


Stabilis



Topotecan



Tradename

Camtoop	Mexico
Cantop	India
Hycamtin	Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Croatia, Denmark, Egypt, Finland, France, Germany, Great Britain, Greece, Hungary, Iceland, Ireland, Italy, Japan, Luxembourg, Malaysia, Netherlands, Norway, Poland, Portugal, Romania, Saudi Arabia, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, United States of America, Venezuela
Oncotecan	Colombia, Ecuador
Potactasol	Argentina, Belgium, Croatia, Finland, Germany, Hungary, Ireland, Italy, Norway, Romania, Slovenia
Topodria	Colombia
Topokebir	Argentina
Topotecan	Argentina, Belgium, Brazil, Canada, Chile, Colombia, Croatia, Finland, France, Germany, Great Britain, Hungary, Ireland, Italy, Norway, Peru, Romania, Spain, Sweden, Switzerland
Topotel	Egypt
Toranex	Mexico
Tpopoxin	Turkey



Stability in solutions

		1 mg/ml	2-8°C		48			753
		1 mg/ml	2-8°C		28			1425
		1 mg/ml	25°C		48			753
		1 mg/ml	25°C		28			1274
		1 mg/ml	25°C		28			1425

		1 mg/ml	4°C		28			1274
		1 mg/ml	5°C		28			823
		0,05 mg/ml	23-24°C		24			1075
		0,05 mg/ml	5°C		7			1075
		0,01 >> 0,05 mg/ml	2-8°C		28			1425
		0,01 >> 0,05 mg/ml	25°C		28			1425
		0,025 mg/ml	23°C-24°C		24			1075
		0,025 mg/ml	5°C		7			1075
		0,05 mg/ml	23-24°C		24			1075
		0,05 mg/ml	5°C		7			1075
		0,05 & 0,025 mg/ml	25°C		28			1274
		0,05 & 0,025 mg/ml	4°C		28			1274
		0,01 mg/ml	25°C		7			1274
		0,05 mg/ml	23-24°C		24			1075
		0,05 mg/ml	5°C		7			1075
		0,01 & 0,05 mg/ml	25°C		21			1274
		0,01 & 0,05 mg/ml	4°C		21			1274
		0,01 >> 0,05 mg/ml	2-8°C		28			1425
		0,01 >> 0,05 mg/ml	25°C		28			1425



Stability of mixtures















		0,05 mg/ml	20°C-25°C		Palonosetron hydrochloride : 25 µg/ml	4		1976
		0,028 mg/ml	20°C-23°C		Carboplatin : 0,45 mg/ml	4		1026
		0,028 mg/ml	20°C-23°C		Cimetidine hydrochloride : 2,88 mg/ml	4		1026
		0,028 mg/ml	20°C-23°C		Cisplatin : 0,084 mg/ml	4		1026
		0,028 mg/ml	20°C-23°C		Cyclophosphamide : 10 mg/ml	4		1026
		0,028 mg/ml	20°C-23°C		Doxorubicin hydrochloride : 1 mg/ml	4		1026
		0,028 mg/ml	20°C-23°C		Etoposide : 0,2 mg/ml	4		1026
		0,028 mg/ml	20°C-23°C		Granisetron hydrochloride : 0,01 mg/ml	4		1026
		0,028 mg/ml	20°C-23°C		Ifosfamide : 7,14 mg/ml	4		1026
		0,028 mg/ml	20°C-23°C		Methylprednisolone sodium succinate : 1,2 mg/ml	4		1026

		0,028 mg/ml	20°C-23°C		Metoclopramide hydrochloride : 0,86 mg/ml	4		1026
		0,028 mg/ml	20°C-23°C		Ondansetron hydrochloride : 0,24 mg/ml	4		1026
		0,028 mg/ml	20°C-23°C		Paclitaxel : 0,27 mg/ml	4		1026
		0,028 mg/ml	20°C-23°C		Prochlorperazine edysilate : 0,096 mg/ml	4		1026
		0,028 mg/ml	20°C-23°C		Vincristine sulfate : 0,5 mg/ml	4		1026



Compatibility

	Topotecan : 0.056 mg/ml Carboplatin : 0.9 mg/ml		1026	
	Topotecan : 0.056 mg/ml Cimetidine hydrochloride : 5.76 mg/ml		1026	
	Topotecan : 0.056 mg/ml Cisplatin : 0.168 mg/ml		1026	
	Topotecan : 0.056 mg/ml Cyclophosphamide : 20 mg/ml		1026	
		Topotecan : 0.056 mg/ml Dexamethasone sodium phosphate : 4 mg/ml		1026
	Topotecan : 0.056 mg/ml Dexamethasone sodium phosphate : 4 mg/ml		1026	
	Topotecan : 0.056 mg/ml Doxorubicin hydrochloride : 2 mg/ml		1026	
	Topotecan : 0.056 mg/ml Etoposide : 0.4 mg/ml		1026	
	Topotecan : 0.056 mg/ml Fluorouracil : 50 mg/ml		1026	
		Topotecan : 0.056 mg/ml Fluorouracil : 50 mg/ml		1026
	Topotecan : 0.1 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423	
	Topotecan : 0.056 mg/ml Granisetron hydrochloride : 0.02 mg/ml		1026	
	Topotecan : 0.056 mg/ml Ifosfamide : 14.28 mg/ml		1026	
	Topotecan : 0.056 mg/ml Methylprednisolone sodium succinate : 2.4 mg/ml		1026	
	Topotecan : 0.056 mg/ml Metoclopramide hydrochloride : 1.72 mg/ml		1026	
		Topotecan : 0.056 mg/ml Mitomycin : 0.084 mg/ml		1026
	Topotecan : 0.056 mg/ml Ondansetron hydrochloride : 0.48 mg/ml		1026	
	Topotecan : 0,1 mg/ml Oxaliplatin : 0,5 mg/ml		1662	
	Topotecan : 0.056 mg/ml Paclitaxel : 0.54 mg/ml		1026	

		Topotecan : 0,1 mg/ml Palonosetron hydrochloride : 50 µg/ml		1976
		Topotecan : 0.1 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Topotecan : 0.056 mg/ml Prochlorperazine edysilate : 0.192 mg/ml		1026
		Topotecan : 0.056 mg/ml Ticarcillin / clavulanic acid : 47.6/1.6 mg/ml		1026
		Topotecan : 0.056 mg/ml Ticarcillin / clavulanic acid : 47.6/1.6 mg/ml		1026
		Topotecan : 0.056 mg/ml Vincristine sulfate : 1 mg/ml		1026



Route of administration











































References

	Type	Publication
753	Manufacturer	Topotecan (Topotecan Medac®) - Summary of Product Characteristics Medac 2016
823	Journal	Patel K, Craig SB, McBride MG, Palepu NR. Microbial inhibitory properties and stability of topotecan hydrochloride injection. Am J Health-Syst Pharm 1998 ; 55: 1584-1587.
1026	Journal	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1075	Journal	Craig SB, Bhatt UH, Patel K. Stability and compatibility of topotecan hydrochloride for injection with common infusion solutions and containers. J Pharm Biomed Anal 1997 ; 16: 199-205.
1274	Journal	Krämer I, Thiesen J. Pharmazeutische aspekte von topotecan-infusionen. TAP Pharmazeutische Zeitung 1997 ; 31: 30-33.
1423	Journal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1425	Journal	Krämer I, Thiesen J. Stability of topotecan infusion solutions in polyvinylchloride bags and elastomeric portable infusion devices. J Oncol Pharm Practice 1999 ; 5: 75-82.
1662	Journal	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1953	Journal	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.

1976	Journal	Trissel LA, Xu QA. Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 9, 3: 238-241.
------	---------	---



Dictionary

 Anticancer drug	 injection
 Tradename	 Stability in solutions
 Container	 Molecule
 Concentration	 Temperature
 Storage	 Duration of stability
 Biosimilar	 conflicting data
 References	 Glass
 Water for Injection	 Not specified
 Hour	 Protect from light
 Day	 NaCl 0,9% or Glucose 5%
 Light	 Polyvinyl chloride
 Sodium chloride 0,9%	 Polyolefine
 Polyisoprene elastomer	 Stability of mixtures
 Solvent	 Compound
 Glucose 5%	 Not specified
 Compatibility	 Compatible
 Immediate turbidity	 Incompatible
 Color change	 Chemical instability
 Route of administration	 Intravenous infusion
 References	 Dictionary